SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

bluebird bio is to ask regulators to restart clinical ... evidence demonstrating that it is very unlikely our BB305 lentiviral vector played a role in this case and we have shared with the FDA ...

Bluebird bio’s lentivirus-vector treatment, Lyfgenia, will cost even more: up to $3.1 million. The companies are currently in negotiations with insurance providers regarding coverage of the drugs.

bluebird bio, Inc. (NASDAQ: BLUE ... in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

About bluebird bio, Inc. bluebird bio is pursuing curative ... effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy ...

SOMERVILLE, Mass., November 06, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual ...